Table 2. (Continued)   


<td><table  border="1"><thead><tr><td></td><td colspan="9"><b> PKC isoform</b></td><td></td><td></td></tr><tr><td><b>Cell line</b></td><td><b>α</b></td><td><b>βI/βII</b></td><td></td><td><b>8</b></td><td><b>8</b></td><td></td><td><b>θ</b></td><td><b>#</b></td><td><b>入/L</b></td><td><b>Detection *</b></td><td><b>Reference</b></td></tr></thead><tbody><tr><td>WM115 (primary)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[36]</td></tr><tr><td>WM1205Lu (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[36]</td></tr><tr><td>SK-Mel 28 (metastatic)</td><td>+</td><td>一</td><td>一</td><td>+</td><td>+</td><td>ND</td><td>+</td><td>+</td><td>ND</td><td>W,R</td><td>[29]</td></tr><tr><td>A375 (primary)</td><td>+</td><td>一</td><td>一</td><td>+</td><td>+</td><td>ND</td><td>+</td><td>+</td><td>ND</td><td>W, R</td><td>[29]</td></tr><tr><td>Murine</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>一</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>N</td><td>[37]</td></tr><tr><td>B16-F1 (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[38]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>一</td><td>一</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>+</td><td>ND</td><td>N</td><td>[39]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>一</td><td>一</td><td>一</td><td>ND</td><td>ND</td><td>+</td><td>ND</td><td>W</td><td>[30]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[40]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>一</td><td>一</td><td>一</td><td>+</td><td>+</td><td>+</td><td>ND</td><td>+</td><td>W</td><td>[41]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[42]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>W</td><td>[43]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>一</td><td>-</td><td>+</td><td>+</td><td>一</td><td>ND</td><td>+</td><td>ND</td><td>W</td><td>[44]</td></tr><tr><td>B16-BL6 (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[45]</td></tr><tr><td>B16-BL6 (metastatic)</td><td>ND</td><td>ND</td><td>ND</td><td>一</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td></tr></tbody></table></td>


\* N: Northern blot, F: Flow cytometry, W: Western blot, R: Reverse transcription-polymerase chain reaction. \*\* Not determined.  

the  $\beta$  isoform in melanocytes [49], and further showed that PKC inhibitor reduces pigmentation in murine skin in vivo [50]. It is interesting to assume that the  $\beta$  isoform is indispensable for the regulation of the tyrosinase activity, but melanin is detected even in the melanoma cells lacking the PKC  $\beta$  isoform [25,27]. On the other hand, the  $\alpha$  isoform is increased in murine B16 melanoma cells treated with retinoic acid [37,39], and the induction as well as the overexpression of this PKC isoform enhances the melanin synthesis, suggesting the involvement of the  $\alpha$  isoform in melanogenesis [38]. The level of the  $\alpha$  isoform is also elevated in B16 cells cultured with mannosylerythiritol lipid, a novel extracellular glycolipid from yeast that induces differentiation of HL-60 promyelocytic leukemia cells [44]. The introduction of antisense oligodeoxynucleotides against the  $\alpha$   isoform prevented mannosylerythiritol lipid-induced melanogenesis, and the expression of the  

Table 3. The expression of PKC isoforms in human melanoma cells in vivo   


<td><table  border="1"><thead><tr><td></td><td colspan="9"><b> PKC isoform</b></td><td></td><td></td><td></td></tr><tr><td><b>Origin</b></td><td><b>Clinical type*</b></td><td><b>α</b></td><td><b>βI/βⅡI</b></td><td><b>y</b></td><td><b>8</b></td><td><b>8</b></td><td><b>n</b></td><td><b>θ</b></td><td></td><td><b>入/</b></td><td><b>Detection**</b></td><td><b>Reference</b></td></tr></thead><tbody><tr><td>Primary</td><td>ALM</td><td>+</td><td>一</td><td>一</td><td>+</td><td>+</td><td>ND***</td><td>ND</td><td>+</td><td>ND</td><td>W</td><td>[25]</td></tr><tr><td>Metastatic</td><td>Unknown</td><td>+</td><td>一</td><td>一</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>+</td><td>ND</td><td>W</td><td>[25]</td></tr><tr><td>Metastatic</td><td>NS (5 cases)</td><td>ND</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>I</td><td>[27]</td></tr><tr><td>Metastatic</td><td>NS (5 cases)</td><td>ND</td><td>一</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>I</td><td>[27]</td></tr><tr><td>Metastatic</td><td>SSM</td><td>+</td><td>+</td><td>一</td><td>+</td><td>+</td><td>+</td><td>一</td><td>+</td><td>+</td><td>W</td><td>[28]</td></tr><tr><td>Metastatic</td><td>NS (5 cases)</td><td>+</td><td>+</td><td>一</td><td>+</td><td>+</td><td>+</td><td>一</td><td>+</td><td>+</td><td>W</td><td>[28]</td></tr><tr><td>Metastatic</td><td>ALM(2cases)</td><td>+</td><td>+</td><td>一</td><td>+</td><td>+</td><td>+</td><td>一</td><td>+</td><td>+</td><td>W</td><td>[28]</td></tr><tr><td>Primary</td><td>ALM</td><td>一</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>1</td><td>[36]</td></tr><tr><td>Primary</td><td>ALM (11 cases)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>1</td><td>[36]</td></tr><tr><td>Primary</td><td>SSM (7 cases)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>I</td><td>[36]</td></tr><tr><td>Metastatic</td><td>ALM (2 cases)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>I</td><td>[36]</td></tr><tr><td>Metastatic</td><td>SSM (2 cases)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>I</td><td>[36]</td></tr></tbody></table></td>


\*ALM: acral lentiginous melanoma: SSM: superficial spreading melanoma, NS: not stated.  $^{**}\mathrm{W}$  Western blot,I: immunohistochemistry. \*\*\*Not determined.  